Actemra

Actemra Indications/Uses

tocilizumab

Manufacturer:

Roche

Marketer:

DKSH
Full Prescribing Info
Indications/Uses
Rheumatoid Arthritis [IV and SC formulations]: Actemra, in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs), is indicated for: the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX [IV formulation only]; the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists [IV and SC formulations].
In these patients, Actemra can be used alone in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.
Polyarticular Juvenile Idiopathic Arthritis (pJIA) [IV formulation only]: Actemra is indicated in combination with methotrexate (MTX) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Actemra can be given alone in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
Systemic Juvenile Idiopathic Arthritis (sJIA) [IV formulation only]: Actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDS and systemic corticosteroids. Actemra can be given alone or in combination with MTX.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in